Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 30 and 80 years~* Patients with type 2 diabetes on treatment (HbA1c 6.0-11.0%)~* Carotid plaque on 3D ultrasound~Exclusion Criteria:~* Acute bleeding or bleeding tendency~* Diagnosed with heart failure~* Suggestive of ischemia on ECG~* Uncontrolled hypertension~* Recently diagnosed with peptic ulcer disease~* Taking other antiplatelet agents~* Hypersensitivity to salicylic acid~* Aspirin induced asthma~* Severe kidney, liver, heart disease

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cilostazol group (Type: EXPERIMENTAL): Cilostazol 200 mg or maximal tolerate dose
- Aspirin group (Type: ACTIVE_COMPARATOR): Aspirin 100 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).